Trial
NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
Infinity Pharmaceuticals, Inc.
Condition
Chronic Lymphocytic Leukemia
Intervention
Duvelisib
Why stopped
Study Stopped
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-26